Limited evolution of the yellow fever virus 17d in a mouse infection model

Emerg Microbes Infect. 2019;8(1):1734-1746. doi: 10.1080/22221751.2019.1694394.

Abstract

By infecting mice with the yellow fever virus vaccine strain 17D (YFV-17D; Stamaril®), the dose dependence and evolutionary consequences of neurotropic yellow fever infection was assessed. Highly susceptible AG129 mice were used to allow for a maximal/unlimited expansion of the viral populations. Infected mice uniformly developed neurotropic disease; the virus was isolated from their brains, plaque purified and sequenced. Viral RNA populations were overall rather homogenous [Shannon entropies 0-0.15]. The remaining, yet limited intra-host population diversity (0-11 nucleotide exchanges per genome) appeared to be a consequence of pre-existing clonal heterogeneities (quasispecies) of Stamaril®. In parallel, mice were infected with a molecular clone of YFV-17D which was in vivo launched from a plasmid. Such plasmid-launched YFV-17D had a further reduced and almost clonal evolution. The limited intra-host evolution during unrestricted expansion in a highly susceptible host is relevant for vaccine and drug development against flaviviruses in general. Firstly, a propensity for limited evolution even upon infection with a (very) low inoculum suggests that fractional dosing as implemented in current YF-outbreak control may pose only a limited risk of reversion to pathogenic vaccine-derived virus variants. Secondly, it also largely lowers the chance of antigenic drift and development of resistance to antivirals.

Keywords: YFV-17D; Yellow fever virus; fractional dosing; intra-host evolution; live-attenuated vaccine; virus diversity.

MeSH terms

  • Animals
  • Antibodies, Viral / blood
  • Brain / pathology
  • Brain / virology
  • Disease Models, Animal
  • Evolution, Molecular*
  • Genetic Variation*
  • Mice
  • Plasmids / genetics
  • Yellow Fever / virology*
  • Yellow Fever Vaccine
  • Yellow fever virus / genetics*

Substances

  • Antibodies, Viral
  • Yellow Fever Vaccine

Grants and funding

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 733176 (RABYD-VAX consortium), No 734584 (ZikaPLAN) and No 734548 (ZIKAlliance). B.V. was supported by a postdoctoral grant of the FWO (Fonds Wetenschappelijk Onderzoek Vlaanderen).